TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03481452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
Study: NCT00742911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate
Description: Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily
Study: NCT00871156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine, Tafenoquine
Description: Chloroquine and Tafenoquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine, Tafenoquine
Description: Chloroquine and Tafenoquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03720678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
Study: NCT01373151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
Study: NCT01363544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: 30 sessions of theta/beta neurofeedback within 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 sessions of individual sports training during 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
Study: NCT03440060

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: procalcitonin
Description: procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
Study: NCT03243682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bidirectional Shock Wave Lithotripsy
Description: the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
Study: NCT02395068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
Study: NCT03243682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Shock Wave Lithotripsy
Description: the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
Study: NCT04482959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: (1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Physiological solution will be used as placebo
Study: NCT03767829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AAT02
Description: ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AAT02
Description: ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
Study: NCT02097173

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Study: NCT04801277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture on acupoints vs sham points
Description: Randomized double blinded clinical trial

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture on acupoints vs sham points
Description: Randomized double blinded clinical trial
Study: NCT04624087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: food-specific go/no-go computerized training
Description: Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: food-specific go/no-go computerized training
Description: Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonfood-specific go/no-go computerized training
Description: Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
Study: NCT04846777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindfulness ecological momentary intervention
Description: Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring placebo
Description: Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
Study: NCT04548102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fetal movement count
Description: Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
Study: NCT03583775

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: Cardiovascular Magnetic Resonance Imaging or MRI exam from children's with congenital heart disease
Study: NCT00586612

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ penta
Description: Intramuscular injection, 3 doses in the primary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ penta
Description: Intramuscular injection, 3 doses in the primary study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ IPV
Description: Intramuscular injection, 1 dose in the Booster study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ IPV
Description: Intramuscular injection, 1 dose in the Booster study.
Study: NCT02862522

Intervention type: OTHER
Intervention: Questionnaire of overall health
Description: The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.

Intervention type: OTHER
Intervention: Questionnaire of overall health
Description: The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
Study: NCT01879553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
Study: NCT00847080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin phosphate 100 mg per day per 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet per day per 2 weeks
Study: NCT04322903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passport to Freedom (P2F)
Description: During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
Study: NCT02753543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Study: NCT04337853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral stent
Description: Radiotherapy with intraoral stent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intraoral stent
Description: Radiotherapy without intraoral stent
Study: NCT04389203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral tubal disconnection + Spontaneous follow up for pregnancy
Description: Unilateral tubal disconnection + Spontaneous follow up for pregnancy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral tubal disconnection + ICSI
Description: Unilateral tubal disconnection + ICSI
Study: NCT03294694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
Study: NCT03787836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintained Exercise
Description: Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased Intensity
Description: Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity.
Study: NCT01334424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
Study: NCT03350932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory imagination about foods
Description: In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
Study: NCT00955175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Given 5 days a week for 20, 22, or 24 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Given 5 days a week for 20, 22, or 24 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Given 5 days a week for 20, 22, or 24 fractions
Study: NCT00652470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Third Ventriculostomy
Description: A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF Shunt Insertion
Description: The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
Study: NCT00649636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Capsules 40 mg
Description: 40mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prozac Pulvules 40 mg
Description: 40mg, single dose fasting
Study: NCT02939963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATC then pressure support 7 cm H2O PEP 4 cm H2O
Description: spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure support 7 cm H2O PEP 4 cm H2O then ATC
Description: 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
Study: NCT00126503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03283735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elderly Enablement
Description: The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
Study: NCT02383524

Intervention type: PROCEDURE
Intervention: Lumbar Radiofrequency Medial Branch Neurolysis
Description: Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
Study: NCT01954849

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Study: NCT04611100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)
Description: Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent